Valeant Model Not Sustainable, Allergan Says
This article was originally published in The Gray Sheet
Executive Summary
Allergan officially rejects Valeant’s buyout offer and lays out its case for staying independent. The drug and device maker looked to bolster shareholder confidence by increasing its guidance and sharing its business plan for the future.